secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001714899-25-000208
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali secures $275M royalty funding from Royalty Pharma on tividenofusp alfa
-----------------------------------------------------------------------------

- Royalty Pharma pays $200M at close conditional on FDA accelerated approval by June 30, 2026.
- Additional $75M due upon EMA approval by Dec 31, 2029; royalty rate 9.25% on worldwide net sales.
- Royalty ceases at 3.0x multiple (2.5x if reached by Q1 2039); Denali retains full rights.
- PDUFA target date for tividenofusp alfa BLA is April 5, 2026; MPS II (Hunter syndrome) therapy.
- Denali CFO states funds advance platform and launch preparation without dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/0001714899-25-000208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/dnli-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer